Distinctive germline expression of class I human leukocyte antigen (HLA) alleles and DRB1 heterozygosis predict the outcome of patients with non-small cell lung cancer receiving PD-1/PD-L1 immune checkpoint blockade

BACKGROUND: Nivolumab is a human monoclonal antibody against programmed cell death receptor-1 (PD-1) able to rescue quiescent tumor infiltrating cytotoxic T lymphocytes (CTLs) restoring their ability to kill target cells expressing specific tumor antigen-derived epitope peptides bound to homologue h...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:J Immunother Cancer
Egile Nagusiak: Correale, Pierpaolo, Saladino, Rita Emilena, Giannarelli, Diana, Giannicola, Rocco, Agostino, Rita, Staropoli, Nicoletta, Strangio, Alessandra, Del Giudice, Teresa, Nardone, Valerio, Altomonte, Maria, Pastina, Pierpaolo, Tini, Paolo, Falzea, Antonia Consuelo, Imbesi, Natale, Arcati, Valentina, Romeo, Giuseppa, Caracciolo, Daniele, Luce, Amalia, Caraglia, Michele, Giordano, Antonio, Pirtoli, Luigi, Necas, Alois, Amler, Evzen, Barbieri, Vito, Tassone, Pierfrancesco, Tagliaferri, Pierosandro
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: BMJ Publishing Group 2020
Gaiak:
Immunotherapy Biomarkers
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC7304840/
https://ncbi.nlm.nih.gov/pubmed/32554614
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/jitc-2020-000733
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak